NCT01640691已完成1 期
A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Immunogenicity Endpoint: hemagglutination inhibition (HAI) titer and microneutralization (MN) titer
研究概览
简要总结
The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza A (H5N1) in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or non-pregnant female (as indicated by a negative urine pregnancy test immediately on the day prior to first vaccine administration) between 20 to 60 years of age at the time of the first vaccination. Women of childbearing potential agree to practice highly effective birth control throughout the study (from Screening to Month 3).
- •Subjects are free of obvious health problems as judged by investigator (established by medical history and physical examination) before entering the study.
- •Subject is physically and mentally capable of participating in the study and willing to adhere to study procedures to complete all elements of the study diary.
- •Subjects provide signed informed consent after receiving a detailed explanation of the study protocol prior to any study procedures.
排除标准
- •Medical history of physician-confirmed infection with an H5N1 virus or a history of vaccination with an H5N1 influenza vaccine.
- •Subject is at high risk of contracting H5N1 influenza infection (e.g. poultry workers).
- •Has received any other licensed vaccines within 2 weeks for inactivated vaccines or 4 weeks for live vaccines prior to enrollment in this study.
- •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Subject has used oral or parenteral steroids, high-dose inhaled steroids (>800 mcg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days preceding the first dose of study vaccine.
- •Subject has received a blood transfusion or immunoglobulins within 90 days prior to first dose of study vaccine, or planned administration of any blood products during the study period.
- •Subject has a known allergy to eggs or other components of the study vaccine.
- •Subject has a history of severe allergic reactions or anaphylaxis.
- •Subject has a history of Guillain-Barré Syndrome.
- •Subject has an acute illness or temperature greater than 38.0 degrees Celsius by any method within 3 days prior to each vaccination.
- •Subject has confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
- •Subject has a rash, dermatologic condition or tattoos which may interfere with injection site reaction rating.
- •Evidence of substance (alcohol or drug) abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
- •Subjects with abnormal laboratory results at screening:(1) ALT or AST > or = 1 x upper limit of normal (ULN). (2) Creatinine > or = 1 x ULN. (3) Any significant laboratory abnormality as judged by the investigator
- •Females are known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the first study vaccine dose, or are lactating or nursing.
- •Subject has any other condition that disqualifies his/her participation in the study in the opinion of the investigator.
研究组 & 干预措施
Study vaccine (AdimFlu-W)
Experimental
0.5 mL/dose, a total of 2 doses, 21 days apart
干预措施: Pandemic Influenza Vaccine (H5N1) (Biological)
结局指标
主要结局
Immunogenicity Endpoint: hemagglutination inhibition (HAI) titer and microneutralization (MN) titer
时间窗: At Day 43 (21 days after the second dose).
The primary immune response endpoint is to evaluate the seroconversion rate (SCR) in terms of HAI assays at Day 43 (21 days after the second dose).The secondary HAI endpoints are defined as following: 1. SCR for the first vaccination, at Day 22. 2. Seroprotection rates (SPR) for each vaccination, at Day 22 and 43. 3. The geometric mean fold rise (GMFR) for each vaccination, at Day 22 and 43. The supportive immunogenicity endpoints of MN antibodies are SCRs, SPRs and GMFRs at Day 22 and 43.
次要结局
- The secondary objective is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events after vaccination.(At 4 weeks after two doses of study vaccine, 4 weeks apart. Reactogenicity will be recorded for 7 days after each vaccination.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderInfluenzaNCT00979602GlaxoSmithKline4,048
已完成
1 期
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite AllergyPerennial Allergic RhinoconjunctivitisAllergic AsthmaNCT00652223Cytos Biotechnology AG21
已完成
2 期
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in AdultsCOVID-19, SARS CoV 2 InfectionNCT05605470Technovalia, Pty Ltd150
已完成
1 期
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult VolunteersLeishmaniasisNCT01484548Access to Advanced Health Institute (AAHI)36
已完成
1 期
Study of Novel Types 1 and 3 Oral Poliomyelitis VaccinesPoliomyelitisNCT04529538PATH205